Background: The management of severe mitral regurgitation (MR) at the time of left ventricular assist device (LVAD) implantation is controversial. We adopted an approach of systematic repair of severe MR at the time of LVAD implantation and report our experience.
Results:
Patients who underwent MVr were younger than those who did not (nonMVr group) (55 vs 63 years; P ¼ .006), but otherwise had similar preoperative characteristics. The incidence of 30-day mortality (2.6% vs 3.6%; P ¼ .78) and other early major adverse events was similar in both groups. At 3 months, no patient in the MVr group had more than mild MR compared with 7 patients (29%) in the non-MVr group (P < .001). Cardiac catheterization done 3 to 6 months after surgery showed tendency toward greater reduction from preoperative pulmonary artery systolic pressure in the MVr group compared with the non-MVr group (À20 vs À13 mm Hg; P ¼ .10). The cumulative incidence of readmission due to congestive heart failure at 2 years was lower in the MVr group than in non-MVr group (7.1% vs 19.7%; adjusted hazard ratio, 0.18; 95% confidence interval, 0.04-0.76; P ¼ .02).
Conclusions: Concurrent MVr at the time of LVAD implantation can be done safely without increase in perioperative adverse events. MVr may be associated with better reduction in severity of MR and may have potential benefit in terms of reduction in readmissions for heart failure. (J Thorac Cardiovasc Surg 2019;157:1841-8)
Explanted heart with left ventricular assist device at transplantation with mitral and tricuspid annuloplasties.
Central Message
Concurrent mitral valve repair at the time of left ventricular assist device implantation can be done safely. It may lead to better reduction in severity of mitral regurgitation and reduced readmissions for heart failure.
Perspective
Management of severe mitral regurgitation at the time of left ventricular assist device implantation is controversial. This study shows that systematic mitral valve repair can be done safely with minimal incremental risk but further studies are necessary to ascertain the benefit.
See Commentary on page 1849.
A substantial proportion of patients presenting for left ventricular assist device (LVAD) implantation have severe mitral regurgitation (MR). Traditionally, severe MR has not been treated surgically during LVAD implantation. 1 In the era of pulsatile devices, the unloading of the left ventricle was such that there was little residual volume in systole, and hence little volume to regurgitate, whereas with the continuous flow devices, significant regurgitation may indicate inadequate left ventricular emptying that could theoretically be overcome by increasing LVAD speed. 1 Additionally, performing surgery on the left sided heart valves during LVAD implantation had historically been associated with early mortality and morbidity. 2 Consequently, majority of patients with severe MR having LVAD implantation did not undergo mitral valve surgery. In the era of continuous flow LVADs, anecdotal experience suggests that persisting severe MR after LVAD implantation can complicate patient management due to occurrence of right sided-heart failure, exercise-induced dyspnea, and persistently elevated pulmonary artery pressures. 3, 4 The question arises as to whether MR should be corrected at time of LVAD implantation. We adopted a protocol of systematic repair of severe MR at the time of LVAD implantation in 2013 and report our outcomes.
METHODS

Study Design and Population
Between March 2011 and July 2017, 234 patients underwent LVAD implantation at our institute. There were 209 HeartMate II (Abbott [St Jude Thoratec Corp], Pleasanton, Calif), 14 HeartMate 3 (Abbott [St Jude Thoratec Corp]), and 11 HVAD (HeartWare International, Inc, Framingham, Mass) devices used. All patients presenting for LVAD implantation were systematically evaluated for severe MR using established echocardiographic criteria. 5 One hundred seven patients (46%) with severe MR on either preoperative transthoracic echocardiography or intraoperative transesophageal echocardiography were defined as having severe regurgitation. From April 2013, all patients with severe MR (78 patients) were planned for concurrent mitral valve repair (MVr) at the time of LVAD implantation (the MVr group). Short-term and midterm outcomes were compared with 28 consecutive historical controls (the non-MVr group) from immediately preceding period (March 2011-March 2013), where severe MR was not treated at the time of LVAD implantation. Median follow-up time was 18.9 months in the MVr group and 16.1 months in the non-MVr group, respectively (patients were censored at time of heart transplantation). This study was approved by the Program for Protection of Human Subjects at the Icahn School of Medicine, Mount Sinai Medical Center. The approval included a waiver of informed consent.
Surgical Techniques
Predominantly, 2 techniques were used: ring annuloplasty or edge-toedge repair.
MVr with ring annuloplasty technique (Video 1). Our technique is described in detail elsewhere. 6 In summary, the procedure was undertaken via median sternotomy. The pericardium was opened and a pocket was prepared for the ventricular assist device as needed depending on the type of implantable LVAD. After heparinization, the aorta was cannulated (or occasionally a peripheral artery in complex reoperations), as were the superior and inferior vena cavae. Cardiopulmonary bypass with mild hypothermia was instituted. The procedure was typically done without crossclamping and without cardioplegic arrest. If there was another indication for aortic clamping, then cardioplegic arrest was used. The apex of the heart was exposed, the ventricle cored, and the apical sewing cuff attached in a standard fashion. The ventriculotomy was left open to prevent systemic ejection of air during the mitral valve repair. We usually intentionally induced ventricular fibrillation at time of coring the apex and left the heart fibrillating until the LVAD support was initiated. The mitral valve was accessed via the trans-septal route with care taken to keep the septal incision entirely within the right atrium (sometime this could inadvertently tear and extend to the dome of the left atrium, requiring later repair of the left atrium). A true-sized complete semirigid ring was then implanted using standard techniques. The interatrial septum was closed. A ring annuloplasty was typically also performed on the tricuspid valve after which the right atriotomy was closed. If the outflow graft anastomosis had not been constructed, then this was done with the aid of a side clamp on the ascending aorta. The heart was de-aired through the apex and the inflow cannula was placed and secured. The outflow graft was connected to the pump, the heart defibrillated, and LVAD support was commenced after satisfactory deairing was achieved.
Edge-to-edge repair (Video 2). This was performed transapically and was undertaken either via sternotomy, subcostal, or left thoracotomy approach, depending on the approach used for LVAD implantation. Procedures were performed on cardiopulmonary bypass without aortic crossclamp. After coring the left ventricular apex, the edges of the ventriculotomy were retracted. Cardiotomy suction device was placed in the left atrium through the ventriculotomy. A 3-0 polyester suture with a felt pledget was passed through the mid-section of the posterior, and anterior leaflets in a horizontal mattress fashion few millimeters from the free margin. The suture was secured with fastening device (Cor-Knot; LSI Solutions, Rochester, NY The choice of repair technique was based on surgeon preference, but there was a bias towards using the edge-to-edge technique if there was a consideration for nonsternotomy LVAD or in sicker patients where an expeditious operation was desirable.
During the study period, 79 patients with severe MR underwent LVAD implantation. One did not undergo MVr and was excluded from further analysis (this was a critically ill patient with multiorgan dysfunction who was being supported with extracorporeal membrane oxygenation support). The 78 remaining patients underwent MVr. Sixty-two patients underwent the ring annuloplasty technique described above. Two patients out of 62 also had leaflet prolapse and required leaflet repair in addition to ring annuloplasty. One with anterior mitral leaflet prolapse received a Gore-Tex (Gore Medical, Flagstaff, Ariz) neochord to A2 and posteromedial commissuroplasty. The other patient had plication of P3. Sixteen patients underwent transapical MVr without annuloplasty (edge-to-edge leaflet or papillary muscle approximation) via the left ventricular apex after coring. The reasons for the transapical approach were mainly use of less invasive nonsternotomy approach (11 patients), presence of critical cardiogenic shock with multiorgan dysfunction (2 patients), and other factors (3 patients). No patient received mitral valve replacement.
Statistical Analysis
Continuous variables were expressed as means AE standard deviation if normally distributed or median and range for skewed distributions. Categorical variables were expressed as frequencies and proportions. Differences between groups were evaluated using the c 2 test or Fisher exact test for categorical variables as appropriate and independentsamples Student t test or the Mann-Whitney U test for continuous variables depending on the distribution. Survival curves of the primary end point of all-cause mortality were constructed with Kaplan-Meier methodology and compared with log-rank test. Patients were censored at the time of heart transplantation, LVAD explantation, or last follow-up if neither transplantation nor explantation had occurred. Cumulative incidence curves for the secondary end points of readmission due to heart failure were constructed with competing risk analysis as death and heart transplantation as a competing event and compared with the Gray test. 7 The multivariable proportional subdistribution hazards model was fit to evaluate the adjusted risk of the secondary end points controlling for concomitant mitral valve repair, age, sex, preoperative systolic pulmonary artery pressure, right ventricular function, tricuspid valve regurgitation, and concomitant tricuspid repair only due to limited number of events and relatively similar baseline comorbidities between the groups. To reduce the potential for overfitting, sensitivity analyses were performed fitting with another model with even more limited number of covariates with concomitant MVr, age, right ventricular function, and tricuspid repair and also with the propensity score adjusted model with only concomitant MVr and propensity scores incorporated as covariates. 8 Propensity scores were calculated using logistic regression for MVr adjusting for all preoperative measured covariates (the C-statistic, 0.83). In each model, proportional hazard assumption was evaluated and valid. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS
Patients
The MVr group patients were younger than the non-MVr group patients (55 vs 63 years; P ¼ .006), but otherwise had similar preoperative demographics and hemodynamics (Table 1) . Notably, both groups had significant pulmonary hypertension (56 vs 57 mm Hg; P ¼ .78) with high pulmonary vascular resistance (4.1 vs 3.5 U; P ¼ .26).
Procedure
In the MVr group, cardioplegic arrest was used in 7 patients for aortic valve repair (n ¼ 4), to facilitate outflow graft anastomosis in presence of aortic calcifications (n ¼ 2), and for concomitant coronary artery bypass grafting (n ¼ 1 Table 1 .
Immediate Outcomes
Short-term operative outcomes are found in Table 2 . There was no significant difference in re-exploration for bleeding (n ¼ 5 out of 78 [6 in the repair group compared with no-repair, respectively. Notably, in the MVr group 5 patients underwent reexploration for bleeding-in 3 there was no surgical source found, 1 patient had a chest wall source, and the other had a bleeding epicardial vessel-no bleeding was thought to be directly related to the mitral valve procedure. The incidence of early major adverse events was similar between the groups, including 30-day mortality (n ¼ 2 out of 78 [2.6%] vs n ¼ 1 out of 28 [3.6%]; P ¼ .44) and stroke (n ¼ 2 out of 78 [2.6%] vs n ¼ 1 out of 28 [3.6%]; P ¼ .44). No right ventricular assist device was used in any of the patients in either the intraoperative or postoperative period. Four (5%) in the MVr group had postoperative right ventricular dysfunction requiring more than 14 days of inotropes compared with 6 (21%) in the non-MVr group. In the MVr group, 1 patient had a pump exchange 2 days after surgery due to device malfunction. Median intensive care unit and hospital stay in the MVr and non-MVr groups were 4 versus 5 days (P ¼ .28) and 17 versus 22 days (P ¼ .02), respectively. Predischarge transthoracic echocardiography confirmed absence of greater than mild MR in all MVr group patients. Median pump speed at discharge for those who underwent HeartMate II LVAD implantation (90% of the study cohort) was 9200 rpm in both groups (P ¼ .42).
Midterm Outcomes and Hemodynamic Parameters Change
Echocardiography done at median of 3 months postoperatively showed no more than mild MR in any patient in the MVr group (n ¼ 0 out of 53) compared with 7 out of 24 (29.2%) patients in the non-MVr group (2 moderate MR and 5 mild-to-moderate MR). There was no documented occurrence of mitral valve endocarditis, ring dehiscence, or return of more than mild mitral valve regurgitation in the MVr group. More detailed echocardiographic data are provided in Table E1 . Cardiac catheterization done within 3 to 6 months of surgery showed a tendency toward greater reduction of the preoperative pulmonary artery systolic pressure in the MVr compared with non-MVr group (Table 3) . The survival at 2 years was 90.2% (95% confidence interval [CI], 78.3%-95.7%) in the MVr group and 79.7% (95% CI, 57.2%-91.2%) in the non-MVr group (adjusted hazard ratio, 0.47; P ¼ .25) (Figure 1 ). The cumulative incidence of readmission due to congestive heart failure at 2 years was lower in the MVr group at 7.1% (95% CI, Values are presented as n (%). LVAD, Left ventricular assist device.
6.9%-37.3%) than the non-MVr group at 19.7% (95% CI, 2.2%-16.0%) (adjusted hazard ratio, 0.18; 95% CI, 0.04-0.76; P ¼ .02) (Figure 2 ). The sensitivity analyses validated these findings (Table E2 ). The transplant surgeons did not experience any specific difficulties at transplantation that were attributed to the MVr.
DISCUSSION
Our data demonstrate that it is feasible to routinely repair the mitral valve at time of implantation of continuous flow LVAD. The procedure can be applied to a wide variety of patients and scenarios and can be done safely, with acceptable early and late outcomes. We were effective in eliminating severe MR in all MVr patients, and this persisted through the follow-up period. We also demonstrated propensity to reduction in pulmonary artery pressures and reduced rate of readmissions with congestive heart failure.
There are theoretical reasons to support elimination of mitral regurgitation by repair of the mitral valve at time of LVAD implantation. Although the volume of MR will typically decrease following implantation of LVAD 9 ; the effectiveness of continuous flow LVADs in unloading the left ventricle, and therefore reducing MR, is variable. In theory, higher revolutions per minute LVAD speeds should abolish regurgitation; however, this is not consistent, and some patients remain with clinically significant regurgitation, despite optimal revolutions per minute settings. Furthermore increasing the revolutions per minute to offset MR can result in worsening right ventricular function due to septal shift. 10 Sometimes severe functional MR cannot be eliminated by increase in revolutions per minute, 3 suggesting that some patients may have a geometric substrate for MR that is independent of ventricular volume. In one study of 90 LVAD recipients, 44% of patients were observed to have at least moderate MR in the follow-up period. 11 Another study found that 34% of patients remained with significant late MR 12 ; severe tethering of the valve was associated with persistence of MR leading the authors to Values are presented as mean AE standard deviation. Data are derived from right heart catheterization data obtained at median follow-up time of 3.9 months in the mitral group (n ¼ 55 out of 78) and 3.7 months in the nonmitral group (n ¼ 20 out of 28). LVAD, Left ventricular assist device; LVEDD, left ventricular end-diastolic diameter; PA, pulmonary artery; PCWP, pulmonary capillary wedge pressure; CVP, central venous pressure; PVR, pulmonary vascular resistance. suggest that there may be a subset in whom MR will not improve despite simple volume reduction of the left ventricle. These observations have led to the question as to whether more predictable elimination of MR (by valve repair or replacement at time of LVAD implantation) could result in improved clinical outcomes.
We have previously been liberal in the use of tricuspid valve repair to optimize right ventricular function after LVAD implantation. 13 Encouraged by the work of Adamson and colleagues 14 who reported use of MVr in 32% of LVAD recipients, we adopted routine MVr, in addition to tricuspid valve repair, in patients with severe MR with the hope of reducing right ventricular afterload, promoting pulmonary vascular remodeling and optimizing right ventricular function. Our initial concern of adding a mitral procedure to an LVAD implantation was the potential for increase in complexity and risk of surgery. We were able to undertake these procedures with minimal incremental morbidity. Our mortality and morbidity was low, and in keeping with that of contemporary series of LVAD implantation. 9, 15 We believe that certain aspects of our approach are key to safely performing mitral surgery at time of LVAD implantation. Avoiding aortic clamping may help preserve right ventricular function by reducing intraoperative ischemic injury. With a trans-septal approach to the mitral valve, the valve can be exposed without excessive retraction and distortion of the aortic valve, allowing the procedure to be done without aortic clamping. We do not downsize the annuloplasty, so risk of inducing functional mitral stenosis should be minimal (we did not observe any cases of mitral stenosis in our series). Although downsizing is accepted as critical in valve repair for secondary mitral regurgitation, this should not apply to the LVAD setting, as the ventricle dimensions will decrease substantially with LVAD support, thus reducing the excessive tethering on the valve leaflets. Valve replacement could be a reasonable alternative to repair, but we believe repair is preferable to minimize valve-related complications, such as endocarditis, paravalvular regurgitation, and thromboembolism (which could negatively influence survival with an LVAD), so we reserve replacement for unrepairable valves. We believe exclusive use of transseptal and transapical approaches has contributed to our lack of bleeding complications directly related to the MVr, because the only cardiac external suture lines remained the right atriotomy and the left ventriculotomy, which is no different than a standard LVAD implant with concurrent tricuspid valve repair. Furthermore, by avoiding an external suture line on the left atrium, doing a mitral repair should not complicate subsequent transplant because there is no suture material or breaching of tissue planes (and hence minimal scarring) in the interatrial groove.
Edge-to-edge repair may be a worthwhile alternative to ring annuloplasty in the LVAD setting, and seemed effective in our limited experience and is particularly attractive for sternal-sparing procedures. The edge-to-edge approach is quicker than annuloplasty and does not require separate septal or atrial incision. Edge-to-edge repair may not be applicable or effective in all cases, such as in the presence of thin leaflets, leaflet prolapse, or severe leaflet tethering. Further study is required to ascertain whether the edge-toedge and annuloplasty techniques are equivalent in safety and effectiveness. Limitations This is a small, single-center retrospective observational series with inherent limitations. Our center is a mitral valve reference center with vast experience in primary MVr, so we were able to seamlessly add a mitral annuloplasty to our LVAD implants. Our experience in non-LVAD MVr is a potential confounding factor and our results may not be generalizable to centers with less MVr experience. Our choice of devices and procedures was varied. However, although we used 3 devices, the predominant device used was HeartMate II (90%). The study was performed over a 7-year period and unmeasured confounders related to the accumulated experience, improvement in perioperative patient care, and changes in surgical techniques, may have influenced the outcomes. There was, for example, a lower threshold to do tricuspid valve repair in the mitral repair cohort. There were also some differences in the baseline status between the groups. However, we do not think that changes in management alone or differing patient cohort selection could explain the clinical, echocardiographic, and hemodynamic differences between our repair patients and controls, because we adjusted for these using multiple methods and on sensitivity analyses our observations remained robust. Our study has a relatively small sample size, and was not adequately powered to precisely quantify differences between the groups-larger studies will be required to elucidate more clearly the benefits of concurrent mitral valve repair.
Future Directions
There have been several prior small studies, although mostly uncontrolled, some suggesting a role for mitral surgery and others suggesting it is unnecessary. A recently published large multicenter analysis based on Interagency Registry for Mechanically Assisted Circulatory Support data included more than 250 mitral valve procedures and found lesser hospitalizations and improved functional status in patients who have MVr, 16 thus supporting our findings. However, all these studies have been retrospectively analyzed. There remains an evidence gap, so there is clear need for prospective studies with randomized or nonrandomized controls. The Interagency Registry for Mechanically Assisted Circulatory Support database or Cardiothoracic Surgical Trials Network could form a repository for such a study where a subset of patients in designated centers with MR at LVAD implantation could be prospectively observed, systematically capturing hemodynamic, echocardiographic, clinical, and quality of life data. A sufficiently powered randomized trial, although ideal, is expensive and time-consuming and may not be a practical priority in the LVAD community at this time.
CONCLUSIONS
Concurrent MVr at the time of LVAD implantation can be done without substantial increase in perioperative adverse events. Our data suggest MVr could have potential benefit in terms of greater reversal of pulmonary hypertension and reduction in hospitalizations for heart failure. Surgical treatment of MR at the time of LVAD may be worth particular consideration in patients with severe MR who are expected to be supported by the LVAD for a prolonged time period.
Webcast
You can watch a Webcast of this AATS meeting presentation by going to: https://aats.blob.core.windows.net/ media/18May01/23BC%203.MCS%20Transplant/S96_6_ webcast_052307017.mp4.
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